Safety and immunogenicity of an autoclaved Leishmania major vaccine

East African Medical Journal

Volumn 77, Issue 9, 2000, Pages 468-470

  Khalil, E A G ^a   Elhassan, A M ^a   Zijlstra, E E ^a   Osman, O F ^b   Eljack, I A ^e   Ibrahim, M E ^a   Mukhtar, M M ^a   Ghalib, H W ^c   Modabbers, F ^d  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b UNIVERSITY OF KHARTOUM   (Sudan)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOCLAVED LEISHMANIA MAJOR VACCINE; PROTOZOAL VACCINE;

ADOLESCENT; ADULT; AGED; ANIMAL; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOGENETICS; IMMUNOLOGY; INFANT; LEISHMANIA; LEISHMANIASIS; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE;

ADOLESCENT; ADULT; AGED; ANIMALS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGENETICS; INFANT; LEISHMANIA; LEISHMANIASIS; MALE; MIDDLE AGED; PROTOZOAN VACCINES; REFERENCE VALUES;

EID: 0034346696     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Satti, M.H. Early phases of an outbreak of kala-azar in the southern Fung. Sudan Med. J. 1958; 1:98-111.
2. Perea, W.A., Moren, A., Ancelle, T. and Sondorp, E. Epidemic visceral leishmaniasis in southern Sudan. Lancet, 1989; 2:1222-1223.
3. De Beer, P., Harith A.E., Grootheest van M. and Winkler A. Outbreak of kala-azar in Sudan. Lancet. 1990; 335:224.
4. Zijlstra, E.E., Siddig, M.A., Elhassan, A.M., Eltoum, I., Satti, M., Ghalib, H.W., Sondorp, E.E. and Winkler A. Kala-azar in displaced people from southern Sudan: epidemiological, clinical and therapeutic findings. Trans, roy. Soc. trop. Med. Hyg. 1991; 85:365-369.
5. EL Hassan, A.M., Hashim, F.A., Siddig, M.A., Ghalib, H.W. and Zijlstra, E.E. Kala-azar in Western Upper Nile in southern Sudan and its spread to a nomadic tribe from the north. Trans. roy. Soc. trop. Med. Hyg. 1993; 87:387-395.
6. Badaro R., Jones T.C., Carvalho, E.M.; Sampaio, D., Reed S.G., Barval A., Teixeira R. and Johnson W.D. New perspective on subclinical forms of visceral leishmaniasis. J. Infect. Dis. 1986; 154: 1003-1011.
7. Sacks D.L., Lal S.L, Shrivastava S.N., Blackwell J. and Neva F. A. An analysis of T-cell responses in Indian kala-azar. J. Immun. 1987; 138:908-913.
8. Kurthzals J.A.L., Hey A.S., Theander T.G. ,Odera E., Christensen C.B.V., Githure J.I., Koech D.K., Schaef K.U., Handman E. and Kharazmi A. Cellular and humoral immune reactivity of a population of the Baringo district of Kenya to Leishmania promastigotes Lipophosphoglycan. Amer. J. trop. Med. Hyg. 1992; 46:480-488.
9. Zijlstra E.E., El Hassan A..M., Ismail A. and Ghalib H.W. Endemic Kalaazar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Amer. J. trop. Med. Hyg. 1995; 52:299-305.
10. Anuradha D., Sharma P., Srivastava J.K., Misra A., Naik S. and Katiyar J.C. Vaccination of langur monkeys (Presbytis entellus) against leishmania donovani with autoclaved L.major plus BCG. Parasitology. 1998; 116:219-221.
11. Sokal J.E. Measurement of delayed skin test responses. N. Engl. J. Med. 1975; 293:501-502.
12. Harith, A.E., Kolk, A..H..J., Kager, P.A., Leeunburg, J., Muigai, R., Kiugu, S. and Laarman, J.J. A simple and economical direct agglutination test for sero-diagnosis and sero-epidemiological studies of visceral leishmaniasis. Trans. roy. Soc. trop. Med. Hyg. 1986; 80:583-587.
13. Mayrink W., daCosta C.A., Magalhaes P.A., Melo M.N., Dias M., Lima A.O., Michalick M.S. and William P. A field trial of a vaccine against American dermal leishmaniasis. Trans. roy. Soc. trop. Med. Hyg. 1979; 73:385-387.
14. Green M.S., Kark J.D., Witztum E., Greenblat C.L. and Spira D.T. Frozen L. tropica: the effect of dose, route for administration and storage on the evolution of clinical lesion. Two field trials in the Israel defense forces. Trans. roy. Soc. trop. Med. Hyg. 1983; 77:152-159.
15. Antune-s C.M.F., Mayrink W., Magalhaes P.A., da Cosa C.A., Melo M.N., Dias M., Michalick M.S., William P., Lima A.O. and Vieira J.B. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Intern. J. Epidem. 1986; 15:572-580.
16. Modabber F Experience with vaccines against cutaneous leishmaniasis of man and mice. Parasitology. 1989; 98:S49-S60.
17. Mohebali M., Javadian E.H., Hashemi-Fesharki R., Mohammad zadeh M., Nadim A., Tahvildar-Bidruni G.H. and Mesdaghim A A Trial of non-living crude vaccine against zoonotic cutaneous leishmaniasis. Med. J. Islamic Repub. Iran. 1995; 8:211-215.
18. Bahar K., Dowlati Y., Shidani B., Alimohammaddian M.H., Khamesipour A., Ehsasi S., Hashemi-Feshari R., Ale-Agha S. and Modabber F. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. In: Clinics in Dermatology (Eds.), Dowlati Y. and Modabber F.; Elsevier Science Inc., New York, 1996, 14, 489-495.
19. Sharifi I., Fekri A. R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R.A., Momeni A.Z., Dowlati Y., Godal T., Zicker F., Smith P. and Modabber F. Double-blind randomised controlled vaccine trial of a single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 1998; 351:1540-3.
20. Jarecki-Black J.C., Hallman K.L., James E. R. and Classman A.B. Resistance against Leishmania donovani induced with an aluminium hydroxide vaccine. Ann. Clin. Lab. Sci. 1988; 18:72-77.
21. Rachamim N. and Jaffe C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis, J. Immunology, 1993; 150:2322-2331.